RxDoctor Payments Data

Simonne Hammarquist, MD

General Practice · New Port Richey, FLNPI 1033650551

Payments from drug & device makers

$977in general payments, 2019–2025

Across 35 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$346
  • Bayer$172
  • Amgen$149
  • AstraZeneca$145
  • Exact Sciences$59
  • Inari Medical, Inc.$28
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$94296%
  • Education$354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$977 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$16,781
Medicare patients
34
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$76,829
JanuviaSitagliptin Phosphate46$51,180
OzempicSemaglutide22$34,679
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$23,646
XareltoRivaroxaban23$23,515
TrulicityDulaglutide13$15,733
MounjaroTirzepatide12$12,188
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,704
Tresiba Flextouch U-100Insulin Degludec12$5,792
BreynaBudesonide/Formoterol Fumarate17$4,898
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,883
Gabapentin166$3,342
Albuterol Sulfate HfaAlbuterol Sulfate151$3,256
Levothyroxine Sodium257$3,109
Pantoprazole Sodium105$3,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$76,829103 claims
Lilly USA, LLCTrulicity, Mounjaro$16$27,92225 claims
AstraZenecaBreztri Aerosphere$145$7,70413 claims
AbbVieSynthroid$17$1,90628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →